AstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease, or COPD. It’s the same approach as an FDA-approved drug that Merck acquired last year in a multi-billion dollar deal.
The post AstraZeneca Turns to China for Molecule That Might Top New Merck COPD Drug appeared first on MedCity News.
How Aikido Intel detects malware and vulnerabilities first – Aikido Security
How Aikido Intel detects malware and vulnerabilities first Aikido Security
